Novel identified receptors on mast cells

Helena Migalovich-Sheikhet†, Sheli Friedman†‡, David Mankuta‡ and Francesca Levi-Schaffer∗

1 Department of Pharmacology and Experimental Therapeutics, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
2 Department of Obstetrics and Gynecology, Hadassah University Hospital, Jerusalem, Israel

Edited by:
Ulrich Blank, INSERM U699, Université Paris-Diderot Paris 7, France
Reviewed by:
Ulrich Blank, INSERM U699, Université Paris-Diderot Paris 7, France
Axel Lorentz, University of Hohenheim, Germany

∗Correspondence:
Francesca Levi-Schaffer, Department of Pharmacology and Experimental Therapeutics, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, POB 12065, Jerusalem 91120, Israel.
e-mail: francesca@ekmd.huji.ac.il
† Helena Migalovich-Sheikhet and Sheli Friedman have contributed equally to this work.

BACKGROUND
Mast cells (MC) have the uniqueness of being tissue resident cells packaged with cytoplasmic granules full of preformed mediators of diverse nature, rich in surface receptors that upon ligand binding can induce not only the fast release of the stored mediators, but also the de novo synthesis of arachidonic acid metabolites and a number of chemokines and cytokines. Therefore they play a prominent role in maintaining homeostasis, acting as armed sentinel cells in the tissues, where they reside spanning from mucosal to connective tissues and more. MC have been historically associated with allergy, in which the key receptor is FcεRI. However, their strategic location and potential have clearly demonstrated that MC are more than the primum movens of allergic inflammation; they are very important players also in innate and adaptive immune responses, inflammation, and tissue changes. MC immunomodulatory roles may result in either negative or positive outcome for the host, enhancing, or suppressing certain features of immune/inflammatory responses. A large variety of receptors especially activating and some inhibiting MC functions, have been described. FcεRI, for IgE activation, and c-kit, the receptor of the stem cell factor (SCF), serve as fingerprints in MC characterization and are the topic of other reviews of this series.

Our purpose is to review herewith the expression pattern, function, ligand(s), and signal transduction pathways of some of the most recently described activating and inhibiting receptors identified to be expressed by the MC from different origins. We have mainly reviewed the novel activating receptors and discussed just a few examples of the inhibitory ones. The activating receptors are comprised of chemokines, interleukins (IL), amines, Toll-Like Receptors (TLRs), and others (Table 1). For some of the receptors, if known, the physiological and pathological consequences of their activation and the strategies to modulate their activity for the purpose of therapeutic intervention are also discussed. Evidences from other hematopoietic cells expressing these receptors is provided as a possible insight for their function on MC. Suggested strategies to modulate these receptors’ activity for the purpose of therapeutic intervention are also discussed.

Keywords: mast cells, activating receptors, inhibitory receptors, ligands, signal transduction, function, co-stimulation/cross-talk

CHEMOKINES RECEPTORS
Chemokines are small cytokine-like proteins that regulate leukocyte trafficking under homeostatic and inflammatory conditions (Luther et al., 2002; Homey and Bunemann, 2004; for chemokines receptors (CRs), CRs in MC, see review Juremalm and Nilsson, 2005). CRs, expressed on hematopoietic and lymphatic cells, are regulated by a variety of inflammatory stimuli (Olson and Ley, 2002). For example CXCR1 and CXCR2 are expressed on most leukocytes, but appear to be functionally significant only for neutrophils, monocytes/macrophages, and MC. CXCR3, CXCR5, and CXCR6 were found to be expressed on cells of lymphoid lineage (Olson and Ley, 2002). CXCR3 was later found to be expressed also by MC (Juremalm and Nilsson, 2005). A defined set of chemokines (CCL1–5, CCL11, CCL13, CCL17–18, CCL20, CCL22, CCL26–27, CX3CL1) was identified to initiate and perpetuate atopic skin inflammation (Homey et al., 2006, 2007).
Table 1 | Structural functional data, expression, ligand, and function of some MC receptors discussed in the review.

| Receptor | Ligand | Structural functional data | MC expression | Function |
|----------|--------|---------------------------|---------------|----------|
| Chemokines receptors | For CXCR3-CXCL9, CXCL10, and CXCL11 (Meiser et al., 2008) | GPCR | E.g., CXCR3 protein: human lung MC (Juremalm and Nilsson, 2005) | Migration (Juremalm et al., 2002), signaling events (Lacotte et al., 2009) partial degranulation (Willox et al., 2010) |
| IL15R | IL-15 | α Chain, β chain, γ chain | Protein: mBMMC Expression assumed by function: hCBMC (Jackson et al., 2005) | Migration (Jackson et al., 2005), enhancement of Th1 response, inhibition of allergic inflammation in a murine model of asthma (Ishimitsu et al., 2001) |
| IL18R | IL-18 | Dimeric complex of IL18Ra, IL18Rb | mRNA and protein: mouse mucosal MC and immature MC (Wiener et al., 2008) | Production of IFN γ, GM-CSF, TNF-α and IL-1, IL-13, and/or IL-4 (Nakanishi et al., 2001; Akdis et al., 2011) |
| IL33R (ST2) | IL-33 | Complex: ST2 and IL1RAcP | Protein: mBMMC (Liew et al., 2010) | Degranulation and proinflammatory cytokine production and release (Hsu et al., 2010; Liew et al., 2010) Increasing of pro-inflammatory cytokines (Allakhverdi et al., 2007) production and Th2 response (Ziegler and Artis, 2010) |
| TSLPR | TSLP | Complex: TSLPR with IL7Ra | mRNA: mBMMC (Knisz et al., 2009), Protein: human peripheral blood and hCBMC (Allakhverdi et al., 2007) | |
| TLR | Bacterial and viral proteins | Extracellular leucine rich region, cytoplasmic domain that consists of three homologous regions (box 1, 2, 3) | TLR2 and TLR4 mRNA: immature and mature MC from murine and human origins (Supajatura et al., 2002). TLR2 protein: hCBMC and nasal polyps MC (McCurdy et al., 2003), TLR2 and TLR4 protein: murine intestine MC and murine and rat peritoneal MC (Pietrzak et al., 2011) | de novo synthesis and release of cytokines (McCurdy et al., 2001; Supajatura et al., 2002) |
| CD48 | 2B4, FimH, S. aureus, and M. tuberculosis toxins | Glycosyl-phosphatidyl-inositol (GPI)-anchored protein | Protein: BMMMC and human peripheral blood MC | Allergic effector unit formation, stimulation of mediator release (Elishmereni et al., 2011) |
| S1P2R | S1P | GPCR | Protein: mBMMC and RBL2H3 (Jolly et al., 2004), hMC (Oskeritzian et al., 2010), and hematopoietic progenitors (Price et al., 2009) | Degranulation (Wang et al., 2012) and chemokine and cytokine release (Oskeritzian et al., 2010) trafficking and migration (Spiegel and Milstein, 2011) |
| HR (H1, H2, H3, H4) | Histamine | GPCR | H1R mRNA and protein: (Lippert et al., 2004) low in human skin MC (Lippert et al., 2004; Gibbs and Levi-Schaffer, 2012), higher in HMC-1 cells | H1, H2-intracellular calcium mobilization (Filly et al., 1990) |
| | | | H2R mRNA and protein: human skin MC, and HMC-1 cells (Lippert et al., 2004) | H3-autoregulation of histamine release (Ohkubo et al., 1994) |
| | | | H3R protein: in brain mast cells (Rozniecki et al., 1999) | H4-chemotaxis and intracellular calcium mobilization in mMC (Nordlund et al., 2008), recruitment of effector cells in human (Hofstra et al., 2003) |
| | | | H4R mRNA: mouse MC, hCBMC, and HMC-1 (Hofstra et al., 2003; Gibbs and Levi-Schaffer, 2012), human skin MC (Lippert et al., 2004) | |

(Continued)
### Table 1 | Continued

| Receptor       | Ligand                  | Structural functional data | MC expression                                                                 | Function                          |
|---------------|-------------------------|----------------------------|-------------------------------------------------------------------------------|-----------------------------------|
| 5HTR          | Serotonin               | GPCR                       | mRNA: mBMMC and human CD34+ derived MC (Kushnir-Sukhov et al., 2006)           | Cell migration (Nordlind et al., 2008) |
|               |                         |                            | Adenosine receptors-A1 protein: canine BR mastocytoma                         | hCBMC implicating the A1R in      |
|               |                         |                            | A2a protein: HMC-1, RBL2H3, mBMMC                                            | potentiation, and A2bBR receptor   |
|               |                         |                            | A2b protein: canine BR mastocytoma, HMC-1, RBL2H3, mBMMC                      | in the inhibition of              |
|               |                         |                            | A3 protein: mastocytoma, RBL2H3, mBMMC (Forsythe and Ennis, 1999; Hua et al., 2011) | anti-IgE-induced degranulation     |
|               |                         |                            |                                                                              |                                   |
| Purinergic P1 | Adenosine               | P1: GPCR                   |                                                                              |                                   |
|               |                         |                            |                                                                              |                                   |
| P2X           | ATP                     | P2X: ion pore              | E.g., P2X1, P2X4, P2X7 protein: hCBMC (Bulanova and Bulfone-Paus, 2010). P2X1-4, P2X5-7 mRNA: mBMMC (derived from C57BL/6 mice) | Degranulation, apoptosis           |
|               |                         |                            |                                                                              |                                   |
| P2Y           | ATP, ADP, UTP, UDP, UDP-glucose | P2Y: GPCR       | P2Y receptors (with the exception of P2Y1) protein: mBMMC                     | Degranulation, P2Y13 in RBL2H3 Ca2+ release and release of β-hexosaminidase |
|               |                         |                            | P2Y1, P2Y2, P2Y13, P2Y15, and P2Y11: hCBMC (Feng, et al., 2004)              |                                   |
|               |                         |                            |                                                                              |                                   |
| CD203c        | NAD and nucleotide sugars | Type II-phosphatidylinositol transmembrane proteins with catalytic domain and a C-terminal endonuclease-like domain | mRNA and protein: overexpressed on neoplastic MC in patients with systemic mastocytosis (Hauswirth et al., 2008) | Cleavage of phosphodiester and phosphosulfate bonds (Buhring et al., 2004) |
|               |                         |                            |                                                                              |                                   |
| CRHR          | CRH                     | GPCR                       | mRNA and protein: hCBMC and LAD-2 (Asadi et al., 2012)                        | Production and release of IL-8, TNF, VEGF. Induction of NK-1 gene expression (Asadi et al., 2012) |
|               |                         |                            |                                                                              | Inhibition of MC maturation and   |
|               |                         |                            |                                                                              | activation, regulation of SCF     |
|               |                         |                            |                                                                              | expression (Sugawara et al., 2012) |
|               |                         |                            |                                                                              |                                   |
| Endocannabinoids | Endocannabinoids receptors | GPCR                    | Protein: on human skin MC (Sugawara et al., 2012)                           |                                   |

mRNA, messenger ribonucul acid; MC, mast cell; IL, interleukin; GPCR, G protein coupled receptor; H, human; M, mouse; BMMC, bone marrow mast cells; CBMC, cord blood mast cells; IFNγ, interferon-gamma; GM-CSF, granulocyte-macrophage colony-stimulating factor; TNFα, tumor necrosis factor α; TSLP, thymic stromal lymphopoietin receptor; TLR, Toll-like receptor; 5HTR, 5-hydroxytryptamine receptors; ATP ADP, adenosine 5’-triphosphate, adenosine diphosphate; UDP, uridine diphosphate; NAD, nicotinamide adenine dinucleotide; CRHR, corticotropin-releasing hormone receptor; CRH, corticotropin-releasing hormone; SCF, stem cell factor; S1P, sphingosine-1-phosphate; HR, histamine receptor.

Human MC (hMC) from different origins express at least nine CRs, i.e., CXCR1–4, CX3CR1, CCR1 (further detailed in MC Co-Stimulation), CCR3–5 that may be activated by the respective chemokines, i.e., CXCL1, CXCL5, CXCL8, CXCL14, CX3CL1, CCL5, and CCL11 (Juremalm and Nilsson, 2005). Interestingly, activation of CRs on MC can not only induce their chemotaxis, but also other stimulatory responses. For example, the activation of CXCR3 and CCR2, besides migration also induces human cord blood MC (hCBMC) signaling events or even partial degranulation in the absence of antigen (Willox et al., 2010). The expression of CXCR3 and RANTES (also known as CCL5) on MC is important especially in the migration of MC precursors in the tissues where they undergo final maturation (Juremalm et al., 2002). CCL5/RANTES can induce MC migration through interactions with CCR1 and CCR4 (Juremalm et al., 2002).

CXCR3 is a seven transmembrane (TM) domain G protein coupled receptor (GPCR) that binds the pro-inflammatory, non-ELR motif of CXC chemokines: CXCL9, CXCL10, and CXCL11 (Meiser et al., 2008) and was found to be sensitive to pertussis toxin (Ptx; Willox et al., 2010). Recently, two different variants of CXCR3 have been identified in human: CXCR3B and CXCR3-ALT, both originating from the same gene and produced by alternative splicing of the CXCR3 mRNA (Willox et al., 2010). CXCR3 activation leads to G protein internalization with subsequent calcium influx.
and triggering of mitogen-activated protein kinases (MAPK) and AKT (Protein kinase B, PKB) cascade resulting in cytoskeleton rearrangement and cell movement (Lacotte et al., 2009). Upon activation of this CR, cross-talk between the CXCR3 and FcεRI is possible due to the fact that both these receptors involve phosphoinositide 3-kinases (PI3Ks) signaling. CXCR3 is highly expressed in human lung MC that reside in proximity to the smooth muscle in asthmatics, but is not expressed in human bone marrow MC (hBMMC; Brightling et al., 2005). In human lungs, CXCR3 on MC mediates their migration toward chemokines—secreting airway smooth muscle regions. Additionally, CXCL10 has been shown to be expressed in that region in bronchial asthma biopsy specimens and ex vivo in smooth muscle cells from asthmatics compared to the ones derived from healthy volunteers (Okayama et al., 2008). Because of the importance of chemokines in recruiting inflammatory cells and MC precursors into the tissues, neutralization of chemokines, or antagonists of their receptors is an active investigational field in the pharmaceutical industry.

INTERLEUKIN RECEPTORS AND TSLPR

Interleukins are secreted glycoproteins that bind to their specific receptors and play a role in the communication among leukocytes. In the past decade, a number of new cytokines have been described such as IL-15, IL-18, IL-7, IL-33. Importantly, MC display the receptors for some of the newly identified IL.

THE IL-15 RECEPTOR

The classic IL-15 receptor (IL-15R) consists of a unique α chain, a β chain, and a common γ chain which is shared with the IL-2 receptor (Lorenzen et al., 2006). IL-15R signaling requires DAP10-associated proteins since the IL-15 signaling pathway phosphorylates DAP10 through Jak3. Once activated, IL-15R triggers the activation of Jak3-STAT5 signaling pathway that relays information to the nucleus (Colucci, 2007). IL-15R is expressed in B, T cells, and natural killers cells (NK) and its activation results in cell proliferation and differentiation. IL-15R was recently reported to be expressed on mouse BMMC (mBMMC). It has not yet been reported whether hCBMC express the same receptors. However, IL-15 induced migration of both mBMMC and hCBMC in a dose-responsive and biphasic manner, supports the possibility that this effect is mediated by two distinct IL-15R with different affinities to IL-15 (Jackson et al., 2005). Interestingly, in stimulated dendritic cells (DC), IL-15, and IL-15Rα are preassembled in complexes within the endoplasmic reticulum/Golgi before being released from the cells. In NK, membrane bound IL-15-IL-15Rα complexes, and not the soluble ones, trigger activation (Mortier et al., 2008).

The ligand of IL-15R, IL-15, is produced in human by both non-immune cells (keratinocytes and skeletal muscle cells) and by immune cells (monocytes, and activated CD4+ T cells) in response to signals that induce innate immunity (Akdis et al., 2011). IL-15 is also produced by murine MC, especially after stimulation with lipopolysaccharide (LPS; Orinska et al., 2007). IL-15 in MC induces an intracrine signal that downregulates chymase-dependent, MC-mediated innate immunity (Orinska et al., 2007). In Il-15−/− mice, the absence of IL-15 in MC increases chymase activities, leading to greater MC bactericidal responses, increased processing, and activation of neutrophil-recruiting chemokines, and improved sepsis survival (Orinska et al., 2007).

IL-15 is associated with autoimmune and inflammatory diseases and was recently shown to be upregulated in T cell-mediated inflammatory disorders, such as rheumatoid arthritis (RA) and inflammatory bowel diseases (Waldmann, 2004). In rheumatoid synovial tissue explants, ulgE induced MC activation induces changes in the amounts of released tryptase, TNFα, and IL-1β by a proportion of mononuclear inflammatory cells, but not in the amount of IL-15 (Woolley and Tetlow, 2000). IL-15 is also associated with the development of X-linked severe combined immunodeficiency (Akdis et al., 2011). Overexpression of IL-15 in vivo enhances Th1 responses, which inhibit allergic inflammation in a murine model of asthma (Ishimitsu et al., 2001). In a human psoriasis xenograft model, the anti IL-15 antibody 146B7 was found to be involved in the reduction of the severity of the disease (Villadsen et al., 2003). Additionally, HuMax-IL-15, a human IgG1 anti-IL-15 monoclonal antibody, that in vitro was able to neutralize exogenous and endogenous IL-15, has been used for clinical trials in patients with RA to perform a phase I–II dose-escalation trial (Baslund et al., 2005; Waldmann, 2006).

THE IL-18 RECEPTOR

IL-18 receptor (IL-18R) expressed on MC belongs to the IL-1 receptor (IL-1R) family (Thomassen et al., 1998). IL-18Ra is the binding chain and together with IL-18Rβ form a high affinity heterotrimetric complex with the ligand IL-18. This complex recruits the intracellular adapter molecules myeloid differentiation primary response protein 88 (MyD88), IL-1 receptor-associated kinases (IRAK) and tumor necrosis factor receptor associated factor 6 (TRAF6) which results in the activation of p38 MAPK, JUN N-terminal kinase (JNK), and/or nuclear factor kB (NF-kB; Arend et al., 2008). IL-18R is expressed on T cells, NK cells, macrophages, epithelial cells, chondrocytes (Kunikata et al., 1998), and MC (Helmy and Grecis, 2002).

The ligand of IL-18R, IL-18, is an IFN-γ-inducing factor and a potent cytokine that is produced by monocytes/macrophages as a reaction to different microbial components and therefore plays a major role in the innate immune responses to pathogens (Arend et al., 2008). Also Kupffer cells, keratinocytes, osteoblasts, astrocytes, and DC express IL-18 (Akdis et al., 2011). The regulation of IL-18 biological activity is carried out by caspase-1-mediated cleavage of pro-IL-18 to the mature protein. Human chymase can also cleave pro-IL-18 to the active protein (Ometto et al., 2006). IL-18 binding protein (BP) is a soluble protein that by binding mature IL-18 prevents its binding to receptor, and therefore serves as a natural inhibitor (Novick et al., 1999). IL-18BP displays four isoforms in humans and two in mice that are the result of alternative splicing of mRNA and which mainly differ in the C-terminal region. IL-18 indirectly increases the production of its own inhibitor in a feedback loop via IFNγ secretion. IL-18R activation is able to induce in addition to IFNγ, also GM-CSF, TNFα, and IL-1 production. In addition it can induce IL-13 and/or IL-4 production by NK, MC, and basophils. It can therefore enhance innate immunity and both Th1 and Th2 driven immune responses (Nakanishi et al., 2001).

IL-18 has been associated with autoimmune diseases or inflammatory disorders, bronchial asthma (Harada et al., 2009), atopic
IL-33 receptor (IL-33R) termed also ST2 is a member of the IL-1R family, and TLR/IL-1R (TIR) superfamily (Liew et al., 2010). It binds IL-33 as a heterodimer consisting of ST2 and IL-1R accessory protein. The signaling cascade of ST2 activation involves recruitment of MyD88, TRAF6, and IRAK. This leads to NF-κB activation and the activation of MAPK p38, signal-regulated kinase ERK, and JNK. ST2 is expressed on basophils, MC, eosinophils, NK cells, Th2 cells, DC, and nuocytes (Kunikata et al., 1998; Akdis et al., 2011).

Mouse BMNC express high levels of ST2 and respond directly to IL-33 to produce a spectrum of inflammatory cytokines and chemokines (IL-1, IL-6, IL-13, TNF, CCL2, and CCL3; Liew et al., 2010). In vivo, IL-33 treatment exacerbated collagen-induced arthritis in ST2−/− KO mice engrafted with MC from WT but not from ST2+−/− mice, a fact that was associated with elevation in expression levels of pro-inflammatory cytokines (Xu et al., 2008). The ST2 ligand, IL-33, is a pro-inflammatory cytokine that activates Th2 response-inducing cells. IL-33 activation induces mBMMC and the murine MC line MC/9 proliferation and Th2 cytokine production including IL-4, IL-5, IL-6, but not IL-33 itself (Hsu et al., 2010). On the other hand mBMMC produce IL-33 in response to IgE activation, which requires calcium influx or ionomycin activation (Hsu et al., 2010).

IL-33/ST2 pathway is critical for the development of IgE-driven tissue inflammation during passive cutaneous anaphylaxis that is a strictly MC-dependent model (Hsu et al., 2010). Levels of soluble ST2 increase in inflammatory conditions such as systemic lupus erythematosus (SLE), RA (Xu et al., 2008), idiopathic pulmonary fibrosis (Tajima et al., 2003), asthma (Oshikawa et al., 2001), progressive systemic sclerosis, Behcet’s disease, Wegener’s granulomatosis, severe trauma, and sepsis (Akdis et al., 2011). Importantly, in all of these conditions MC activation and role have been illustrated. IL-33 release is elevated in skin of patients with atopic dermatitis (Liew et al., 2010). Constant mechanical microtrauma and destruction of skin barrier induce IL-33 release and a pro-inflammatory response. In addition, IL-33 may play a role in psoriasis-like plaque inflammation (Hueber et al., 2011).

IL-33 has been classified as an alarmin/danger signal (Cevikbas and Steinhoff, 2012) since it is released by cells undergoing necrosis and it is inactivated by caspas during cell apoptosis (Liew et al., 2010; Hueber et al., 2011). However, it is evident that IL-33 is released not only from necrotic cells, but also from living cells and therefore acts as a classical cytokine (Liew et al., 2010). Its importance in allergy is the current topic of high interest partly due to its effects on the MC.

TSLP RECEPTOR

TSLP receptor (TSLPR) is the receptor of TSLP that is an IL-7-like cytokine initially identified in the culture supernatant of a thymic stromal cell line (He and Geha, 2010). TSLPR has a low affinity to TSLP, but together with IL-7Rα they generate high affinity binding sites and trigger signaling (Park et al., 2000). Cross species homology of TSLP and its receptor is relatively low (about 40%; He and Geha, 2010; Ziegler and Artis, 2010), but the fact that both in human and in mouse IL-7Rα is required suggests that human TSLP and TSLPR are orthologs to mouse TSLP and TSLPR. The signaling cascade of these receptors is not completely clear and no Janus kinases (JAK) are activated (Isaksen et al., 2002). It has however been shown that receptor engagement can activate the transcription factor STAT3 in human and STAT5 in mouse and human (Isaksen et al., 2002). In addition, it can also induce the expression of common genes (such as Cish; Isaksen et al., 2002).

TSLP receptor is expressed on hematopoietic cell lineages, including B cells, T cells, MC, eosinophils, and DC (Taylor et al., 2009). mBMMC were shown to express TSLPR mRNA (Knisitz et al., 2009). TSLP and IL-7Rα chain expression were determined at the mRNA level on human peripheral blood and hCBMC (Allakhverdi et al., 2007). In spite of these reports, human peripheral blood derived MC (hpBM) and the HMC-1 cell line (hMC leukemia-1) were found by us to express TSLPR, but not IL-7R (Levi-Schaffer, F., Soumelis, V., Levy, I., unpublished data). At the protein level, TSLP was also reported to be expressed in vivo on MC infiltrating the bronchial mucosa of asthmatic patients, as revealed by immunostaining of biopsy specimen (Allakhverdi et al., 2007; Comeau and Ziegler, 2010; Shikotra et al., 2012).

It has been found that MC infiltrating to the mucosal gland stroma and airway smooth muscle in asthma not only express high levels of TSLP mRNA, but can also respond to TSLP (Rochman and Leonard, 2008). TSLP can directly activate hMC to produce pro-inflammatory Th2 cytokines and chemokines in the presence of IL-1α and tumor necrosis factor α (TNF-α), in a way that mimics inflammation conditions (Allakhverdi et al., 2007). Various cell types can produce TSLP: endothelial, epithelial cells and epidermal keratinocytes, airway smooth muscle cells, fibroblasts, DC, trophoblasts, and cancer or cancer-associated cells (Takai, 2012). hMC express TSLP mRNA, which is upregulated upon cross-linking of the IgE receptor. Pre-incubation with IL-4 results in significant upregulation of IgE-mediated TSLP protein and mRNA expression (Okayama et al., 2009; Comeau and Ziegler, 2010).

TSLP plays a significant role in initiation of allergic inflammation and is very important to cells such as the MC, due to its high expression in the interfaces between the body and environment and its ability to lead to Th2 responses (Ziegler and Artis, 2010). Different studies have shown that asthma, allergic rhinitis, and atopic dermatitis are characterized by an increased expression of TSLP in the inflamed tissue (Ziegler and Artis, 2010; Le et al., 2011). Mouse overexpressing TSLP on TCRβ−/− background, develop dermal inflammation and skin infiltrates of MC and eosinophils (Yoo et al., 2005). MC deficient mice failed to upregulate TSLP in nasal epithelium after allergen challenge in a model of allergic rhinitis (Ziegler and Artis, 2010). In asthma it was demonstrated that MC play an important role in TSLP production (Shikotra et al., 2012). TSLP levels are increased in human asthma and correlate with the
As key protagonists of innate immunity, MC play a pivotal role in anti-infection defense and "danger" responses. MC reactivating cytokines and IL-6 (Munoz et al., 2003). Later on we found that S. aureus, a Gram+ bacteria, and its toxins bind to CD48 and TLR2 on hCBMC causing subsequent release of pro-inflammatory cytokines (Rocha-de-Souza et al., 2008). CD48 is illustrated here since in MC, CD48 was first described as a CD2-like molecule, is a 40KD glycosyl-phosphatidylinositol (GPI)-anchored protein, expressed on the surface of hematopoietic cells (recently reviewed in Elishmereni and Levi-Schaffer, 2011). The CD48 structure combines a distal V-like domain with a C2-like domain containing conserved cysteine residues that form disulfide bonds. It lacks a TM domain and is attached to the cell surface by a glycolipid, GPI, restricted to the outer leaflet of the membrane bilayer (Shin and Abraham, 2001). CD48 is found also in soluble form, due to its cleavage upon activation. Stimulated CD48 associates to the kinase LCK and leads to tyrosine phosphorylation (Elishmereni and Levi-Schaffer, 2011).

TOLL-LIKE RECEPTORS AND OTHER BACTERIAL AND VIRAL RECEPTORS
As key protagonists of innate immunity, MC play a pivotal role in anti-infection defense and "danger" responses. MC reactivating cytokines and IL-6 (Munoz et al., 2003). Later on we found that S. aureus, a Gram+ bacteria, and its toxins bind to CD48 and TLR2 on hCBMC causing subsequent release of pro-inflammatory cytokines (Rocha-de-Souza et al., 2008). CD48 is illustrated here since in MC, CD48 was first described as a CD2-like molecule, is a 40KD glycosyl-phosphatidylinositol (GPI)-anchored protein, expressed on the surface of hematopoietic cells (recently reviewed in Elishmereni and Levi-Schaffer, 2011). The CD48 structure combines a distal V-like domain with a C2-like domain containing conserved cysteine residues that form disulfide bonds. It lacks a TM domain and is attached to the cell surface by a glycolipid, GPI, restricted to the outer leaflet of the membrane bilayer (Shin and Abraham, 2001). CD48 is found also in soluble form, due to its cleavage upon activation. Stimulated CD48 associates to the kinase LCK and leads to tyrosine phosphorylation (Elishmereni and Levi-Schaffer, 2011).

CD48
CD48, a CD2-like molecule, is a 40KD glycosyl-phosphatidylinositol (GPI)-anchored protein, expressed on the surface of hematopoietic cells (recently reviewed in Elishmereni and Levi-Schaffer, 2011). The CD48 structure combines a distal V-like domain with a C2-like domain containing conserved cysteine residues that form disulfide bonds. It lacks a TM domain and is attached to the cell surface by a glycolipid, GPI, restricted to the outer leaflet of the membrane bilayer (Shin and Abraham, 2001). CD48 is found also in soluble form, due to its cleavage upon activation. Stimulated CD48 associates to the kinase LCK and leads to tyrosine phosphorylation (Elishmereni and Levi-Schaffer, 2011).

CD48 is illustrated here since in MC, CD48 was first described to be involved in innate immunity as it binds FimH of E. coli. This interaction triggers a strong TNF-α release and the uptake of this Gram-bacteria (Malaviya et al., 1999; Malaviya and Abraham, 2001; Proft and Baker, 2009). CD48, has also been implicated in MC interactions with M. tuberculosis, which triggers the release of several pre-stored mediators, such as histamine and β-hexosaminidase, and the de novo synthesis of cytokines, such as TNF-α and IL-6 (Munoz et al., 2003). Later on we found that S. aureus, a Gram+ bacteria, and its toxins bind to CD48 and TLR2 on hCBMC causing subsequent release of pro-inflammatory cytokines (Rocha-de-Souza et al., 2008). CD48 is overexpressed in murine asthma and was defined as a signature gene in this condition (Zimmermann et al., 2003). The CD48 ligand in human is 2B4, expressed by several hematopoietic cells. CD48/2B4 interactions taking place between MC and eosinophils are important in allergic inflammation giving rise to the physical formation of the allergic effector unit (AEU) between these two cells (Elishmereni et al., 2011). CD48-2B4 binding induces degranulation of MC and increases eosinophil survival and activation (Elishmereni et al., 2011). In a murine model of allergic asthma, treatment with neutralizing CD48 Ab dramatically inhibited the lung inflammation (Muniz et al., 2007). Therefore it seems that CD48 is a good candidate to be blocked on MC in order to avoid both AEU formation and bacterial invasion, with this last property being particularly helpful in allergic conditions, such as atopic dermatitis, that are commonly associated with S. aureus infection.

SIP RECEPTORS
SIPs are GPCRs of sphingosine-1-phosphate (S1P). Secretion of SIP by MC can modulate their function by binding to S1P1 and S1P3, found on MC, in an autocrine fashion (Spiegel and Milstien, 2011). It was shown on DC that there is a cross-talk
between S1PR3 and S1PR1, when upregulation of S1PR3 activates the small GTPase RHO leading to translocation of Four and a half LIM domains protein 2 (FHL2) to the nucleus and downregulates S1PR3 expression. On the other hand, downregulation of S1PR3 increases S1PR3 expression and RAC activation (Spiegel and Milstien, 2011).

S1P1 is involved in the migration of MC toward low concentrations of antigen, while S1P2 participates in FcεR1-induced degranulation (Jolly et al., 2005; Olivera, 2008). S1P released from MC after cross-linking of FcεR1, and their S1P2 receptors are critical for degranulation and chemokine, cytokine, and lipid mediator release from activated human and rodent MC (Oskeritzian et al., 2010). Additionally, blocking of the SIP–S1PR3 axis was shown to drastically reduce circulating levels of histamine in a mouse anaphylaxis model indicating that MC were inhibited (Oskeritzian et al., 2010). The S1P2 activation plays a role in anti-viral immunity: the viral membrane lipid sphingomyelin that is converted in the cell membrane to S1P can then activate the S1PR2 in an autocrine manner to stimulate MC degranulation (Wang et al., 2012). S1P–S1PR1 axis has been shown to be expressed on and to control the trafficking and migration of numerous types of immune cells, including T and B lymphocytes, natural killer T cells, DC, macrophages, neutrophils, hematopoietic progenitors, MC, and osteoclasts (Spiegel and Milstien, 2011).

Therefore, S1PR can offer an interesting pharmacological target for a number of immune diseases. For example the S1PR2 antagonist JTE001 significantly inhibited H2O2-induced permeability in the rat lung perfused model (Sanchez et al., 2007). More studies are under way to exploit the blockage of the S1P and its receptors in many diseases and notably in allergy.

**AMINES’ RECEPTORS**

Among the mediators extensively identified with the function of MC in allergy, histamine in humans and rodents, and serotonin especially in rodents are key factors influencing the activity of a number of target cells/organs. MC not only produce these two potent amines but also display some of their receptors (Gibbs and Levi-Schaffer, 2012; Ritter et al., 2012).

**HISTAMINE RECEPTORS**

Histamine receptors (HRs) are GPCRs with seven TM-spanning helices. Until now, four subtypes of human HRs have been identified: H1R, H2R, H3R, and H4R. H1R and H2R have been the focus of many studies (recently reviewed in Gibbs and Levi-Schaffer, 2012). Fewer studies have been performed on the H3R and even less on the newest identified one, H4R. Regarding HRs expression by MC, not much work had been carried out until the recent discovery of H4R.

H1R expression has been described on human skin MC to be low (Lippert et al., 2004; Gibbs and Levi-Schaffer, 2012), while on the HMC-1 cells it is higher (Lippert et al., 2004). H1R antagonists can inhibit MC activation and therefore can be used as anti-allergic/MC stabilizing drugs (Levi-Schaffer and Eliashar, 2009), even though some of them might increase cellular CAMP in competitive antagonism with H2R. In cholangiocytes, H1R acts by Guq activating IP[3]/Ca2+, whereas H2R activates Go(s) stimulating cAMP (Francis et al., 2012). Additionally, it was reported that H2R can activate both adenylyl cyclase and phospholipase C signaling pathways via separate GTP-dependent mechanisms (Wang et al., 1996). Interestingly, via the H2R, histamine displays a net inhibitory action on MC (Gibbs and Levi-Schaffer, 2012). H2R is expressed on human skin MC, on HMC-1 cells and basophils, and perhaps on human lung MC. The H2 agonist imipramide was shown to inhibit MC activated with compound 48/80 and this inhibition was reversed by the histamine antagonists (Masini et al., 1982).

H3R and H4R have about 40% sequence homology and are functionally related (Morse et al., 2001; Zhu et al., 2001). Both of them are activated by α-methylhistamine (H3/4R agonist) and inhibited by thioperaamide (antagonist). Mouse MC were reported to express H4R and to lack H3R expression (except brain MC that do express H3R; Pillot et al., 2002; Gibbs and Levi-Schaffer, 2012).

In mouse MC, the H4R has been shown to couple to Ca2+ mobilization, but not to CAMP, in a Ptx-sensitive manner (Hofstra et al., 2003; Rosethorne and Charlton, 2011). H4R in mouse MC affects chemotaxis and intracellular calcium mobilization, and although it is not involved in their degranulation, the receptor activation and subsequent histamine release leads to recruitment of effector cells, especially eosinophils, rich in H4R to the site of chronic allergic inflammation (Hofstra et al., 2003). H4R activation of murine MC increases leukotriene B4 (LTB4) release and supports neutrophil recruitment induced by zymosan (Takeshita et al., 2003). H4R blockade was shown to decrease MC and eosinophil migration to the airway epithelial tissue after guinea pigs allergen exposure (Yu et al., 2008). Blocking the H4R also decreases the MC migration in presence of CXCL12 in vitro (Godot et al., 2007). Therefore, H4R plays a role in allergy by mediating the recruitment of cells to the site of allergic inflammation and also by controlling this last effect together with H1R. It has recently been demonstrated that in a mouse model of allergic pruritus, the H4R antagonist JNJ7777120 is more effective in reducing the response to histamine release than H1R antagonist (Dunford et al., 2007). It is foreseen that combinatiorial therapy with both H4R antagonists – when available for human use – to target mostly MC and eosinophils and H1R antagonists could be a potent new therapy for some allergic responses rather than just H1R antagonists.

**SEROTONIN RECEPTORS (5HTRs)**

Serotonin is a neurotransmitter that can modulate a number of functions also outside the neural system (Berger et al., 2009). Serotonin receptors, also known as 5-hydroxytryptamine receptors (5HTRs), are classified in humans into seven main families with an additional subtype for two of the families (IUPHAR Receptor Database, 2008). Although 5HTRs have been known for a long time they have only recently been characterized on MC. With the exception of the 5HTR3, a ligand gated ion channel, all other serotonin receptors are GPCRs (Ritter et al., 2012) that activate an intracellular second messenger cascade to produce an excitatory or inhibitory response.

5HT1AR is negatively coupled to adenyl cyclase via Gi and it is expressed on hMC (Kushnir-Sukhov et al., 2006; Ritter et al., 2012) and mBMMC (Kushnir-Sukhov et al., 2006). It is expressed on MC in normal skin and its activation induces inflammation, due to MC migration and adherence in the site of inflammation, but it does not involve degranulation (Nordlund et al., 2008). Even though a still controversial issue, hMC were found to be able to secrete...
serotonin both in IgE-dependent and independent manner (Askenase et al., 1991; Matsuda et al., 1995). This was further shown to activate effector T cells and macrophages (Young and Matthews, 1995), and also could show the possibility of an autocrine regulation of the MC. 5HT/5HT1AR are involved in allergic contact eczema, atopic eczema, psoriasis (Nordlund et al., 2008), and also expressed in human mastocytosis (Ritter et al., 2012).

**PURINERGIC RECEPTORS AND ATP-HYDROLYZING ENZYMES**

**PURINERGIC RECEPTORS**

Purinergic receptors, also known as purinoceptors, are a family of plasma membrane molecules involved in several cellular functions such as vascular reactivity, apoptosis, and cytokines secretion. The term, purinergic receptor was originally introduced to illustrate specific classes of membrane receptors that mediate relaxation of gut smooth muscle as a response to the release of Adenosine 5'-triphosphate (ATP) – P2R receptors or adenosine – P1R (King and Burnstock, 2002). There are three known distinct classes of purinergic receptors, referred to as P1, P2X, and P2Y receptors comprehending different subtypes (Bulanova and Bulfone-Paus, 2010). P2Y receptors, in addition to ATP, respond also to different nucleotides (ADP, UDP, UTP, UDP, and UDP-glucose). P1 and P2Y are GPCRs whereas P2X is a ligand gated ion channel.

Mast cells from most species express P1Rs: A1, A2A, A2B, and A3 adenosine receptors (Hua et al., 2011). Additionally they express a large variety of P2R. hCBMC, for example, express P2X1, P2X4, P2X7, P2Y1, P2Y2 (Bulanova and Bulfone-Paus, 2010), P2Y12, P2Y13, and P2Y11 (Feng et al., 2004), while mBMMC (derived from C57BL/6 mice) express the mRNA of P2X1-4, P2X6-7, and all P2Y receptors with the exception of P2Y2. P815 mastocytoma cells (derived from DBA/2 mice) express mRNA for all P2X and P2Y receptors (Bulanova and Bulfone-Paus, 2010). Activation of P2XR leads to the formation of a non-selective cationic channel (Burnstock, 2007), that triggers the activation of a number of intracellular signaling molecules, including MAPK, which is connected to cytokine secretion and release. ATP induces purinergic receptor P2X7 mediated membrane permeabilization, apoptosis, and cytokine expression in murine MC (Bulanova et al., 2009).

Stimulation of P2YR generally leads to phospholipase C (PLC) activation that cleaves PI(4,5)P2 to form IP3 and diacylglycerol, an activator of protein kinase C (PKC). Only the P2Y11 receptor is directly coupled to activation of adenylate cyclase (AC) and PLC, while P2Y12, P2Y13, and P2Y14 receptors negatively affect cAMP synthesis (Van Kolen and Slegers, 2006). Extracellular nucleotides activating P2Y receptors are involved in the regulation of MC degranulation. P2Y13 receptor in a rat MC line (RBL-2H3) activation by ADP leads to intracellular calcium mobilization and release of β-hexosaminidase. Nucleotides via P2Y2 mediate chemotaxis in mBMMC and CD34+ progenitors (Bulanova and Bulfone-Paus, 2010).

ATP acts as an autocrine and paracrine factor that enables the intercellular communication. MC IgE-dependent degranulation induces the release of ATP that influences the neural cells via P2X and P2Y receptors (Bulanova and Bulfone-Paus, 2010).

A study recently reported by Yip et al. showed a biphasic effect of adenosine in hCBMC, implicating the A1R in potentiation, and A2BR receptor in the inhibition of anti-IgE-induced degranulation (Yip et al., 2009; Hua et al., 2011). Interestingly, also leukotriene E4 acts as ligand for P2Y12 in LAD-2 cells. In addition it can induce purinergic receptor mediated pulmonary inflammation in mice (Paruchuri et al., 2009). It has been shown that adenosine binding to P1R on airway smooth muscle, goblet cells, MC, and neurons contributes to the pathogenesis of asthma (Okayama et al., 2008; Vieira et al., 2011). Adenosine inhibits and potentiates IgE-dependent histamine release from human lung MCs by an A2 purinoceptor mediated mechanism (Hughes et al., 1984).

Xanthine derived drugs such as theophylline that have been widely used for asthma, have been found to be both antagonists/agonists of adenosine receptors and phosphodiesterase inhibitors on MC. Several antagonists are currently available for research use, such as suramine (Gever et al., 2006). Although the purinergic receptors are well described in the nervous system, their discovery on MC is still relatively new and further research is required in order to understand their specific function and effects on these cells.

**CD203c**

CD203c (E-NPP3) belongs to a family of ecto-nucleotide pyrophosphatase/phosphodiesterases (E-NPPs) that catalyzes the cleavage of phosphodiester and phosphosulfate bonds of a variety of molecules, including deoxynucleotides NAD and nucleotide sugars (Buhring et al., 2004). These type II TM proteins are composed of a short N-terminal cytoplasmic domain, followed by the TM region, two somatomedin-like domains, the catalytic domain and a C-terminal endonuclease-like domain. Recently, CD203c has been defined as a novel activation-linked surface antigen on MC that is upregulated in response to IgE receptor cross-linking and is overexpressed on neoplastic MC in patients with systemic mastocytosis (Hauswirth et al., 2008). CD203c on basophils serves as a marker to diagnose various allergic diseases such as asthma (Ono et al., 2010). The expression and role of ATP-hydrolyzing enzymes for the biology of MC is still under investigation.

**CORTICOTROPIN-RELEASING HORMONE AND ENDOCANNABINOIDS**

Even though Corticotropin-releasing hormone (CRH) and endocannabinoids receptors have been typically described as central nervous system (CNS) receptors involved in regulation of the hypothalamic–pituitary–adrenocortical axis and in drugs response (Goeders and Guerin, 2000; Steiner and Wotjak, 2008), these receptors have also been found to be expressed on hematopoietic cells thus regulating peripheral conditions.

**CORTICOTROCITROPIN RELEASING HORMONE RECEPTORS**

Corticotropic releasing hormone receptors (CRHRs) are GPCRs which are activated by urocortin (UCN), CRH, or substance P and consist of two receptors-CRH-R1 and CRH-R2, each encoded by a separate gene (Theoharides et al., 1998; Slominski et al., 2001; Asadi et al., 2012). CRHR signaling involves cAMP/PKA pathway or alternatively MAPK or intracellular calcium (Ca2+)/PKC pathways, depending on the site of activation (Grammatopoulos, 2011).

CRH-R1 is sensitive to β-arrestin-dependent signaling desensitization and internalization. Receptor endocytosis is also one of
the mechanisms employed by CRH-R1 to induce ERK1/2 and p38 MAPK phosphorylation and activation intermediates (Markovic et al., 2008). CRH-R1 variant is expressed in a tissue-specific manner; it is present in anterior pituitary as well as in peripheral sites such as reproductive tissues (myometrium, endometrium, and chorion trophoblast cells) and MC (Nezi et al., 2010).

Corticotropin-releasing hormone is secreted under stress and activates the hypothalamic–pituitary–adrenal axis. Interestingly a similar network is found in the skin (Asadi et al., 2012). Addition of CRH to the LAD-2 (leukemia MC line cells) primed with substance P induces synthesis and release of IL-8, TNF, and vascular endothelial growth factor (VEGF) 24 h later (Asadi et al., 2012). MC activation by CRH induces gene expression of neurtokinin (NK-1). The ability of CRH to activate MC may explain its pro-inflammatory actions and the pathophysiology of certain skin conditions, which are precipitated or exacerbated by stress, such as atopic dermatitis, eczema, psoriasis, and urticaria (Theoharides et al., 1998). CRH has pro-inflammatory actions not only on its own, but also by augmenting the expression of the respective receptors on human skin MC (Asadi et al., 2012).

**ENDOCANNABINOIDS RECEPTORS**

The cannabinoid receptors are a class of cell membrane receptors belonging to the GPCRs superfamily. They contain seven TM spanning domains and are divided into two subtypes, termed cannabinoid 1 (CB1) and cannabinoid 2 (CB2). The endocannabinoid system has been recognized as a major neuromodulatory system, which functions to maintain brain homeostasis (Steiner and Wotjak, 2008). The CB1 receptor is expressed mainly in the brain CNS, but also in the lungs, liver, and kidneys. The CB2 receptor is expressed mainly in the immune system and in hematopoietic cells (Pacher and Mechoulam, 2011).

**CB1** was found to be expressed on human skin MC (Sugawara et al., 2012) and be activated by endocannabinoids such as anandamide (AEA) and 2-arachidonoylglycerol. CB1 and CB2 receptors can induce inhibition of adenylate cyclase activity and phosphorylation with activation of p42/p44 MAPK, p38 MAPK, and JNK as signaling pathways to regulate nuclear transcription factors. The CB1 receptor regulates K⁺ and Ca²⁺ ion channels, probably via Go/α (Howlett, 2005). A common role of CB1 and CB2 receptors appears to be the modulation of ongoing release of chemical messengers. The activation of CB2 receptors on MC has direct anti-inflammatory effects due to a decrease in mediators released from the cells (Pini et al., 2012).

The best CB2-selective agonists that have been developed so far include L-759633, L-759656, and JWH-133, all structural analogs of D9-THC. Other notable examples are the non-classical cannabinoid, HU-308, and the aminoalkylindole, AM1241 (Pertwee, 2006). The activation of CB1 receptor on bronchial nerve ending has a bronchodilatory effect (Pini et al., 2012). However, inhibiting the enzymatic inactivation of pharmacologically active endogenous molecules that do not serve as endocannabinoids or causing an accumulation of endocannabinoid molecules at non-CB1, non-CB2 targets such as the TRPV1 receptor or the putative abnormal-cannabidiol receptor, might lead to adverse effects.

Endocannabinoids limit excessive MC maturation and activation in human skin in situ and regulate SCF expression, by increasing its production in human hair follicle epithelium via CB1 stimulation (Sugawara et al., 2012). On the other hand in the ovalbumin induced lung sensitization model in CB1 and CB2 deficient mice a reduction in IgE production and attenuation of bronchoalveolar lavage fluid neutrophilia was described (Kaplan et al., 2010). In some studies, activation of CB1R seems to inhibit the allergic inflammation, while in others it is still controversial. Either way, we can conclude that CB1R activation is a potential target to be used in the treatment of allergy, although further research is still required.

**MC RECEPTORS CROSS-TALK**

Cross-talk between receptors might result in co-activation or in inhibition of cell response. Co-stimulation is often required for the development of an effective immune response, and has been recognized to participate in antigen-specific signal from lymphocytes antigen receptors. In the last few years, parallel to the identification of the new MC receptors, some cross-talk effects between receptors were described, resulting either in co-activation (synergism or additive effects) or in inhibition. Most of the works have dealt with the FcεRI mediated MC activation. For example IL-18R, IL-33R, TSLP, and TLRs were found to work via the same signaling pathway which activates MyD88, IRAK, TRAF, and MAPK and NF-kB (Figure 1). GPCRs on MC can also co-interact to produce different responses.

**MC CO-STIMULATION**

Due to co-stimulation and cross-talk significance in modulation of MC activity, we chose to review some recent examples of this phenomenon. CCRs are known stimulatory and co-stimulatory molecules expressed on MC. Fifadara et al. showed for the first time the formation of cytome-like cellular extensions by BMMC, a totally new feature of these cells, upon co-stimulation of FcεRI and CCR1 with antigen and CCR1 ligand, macrophage inflammatory protein-1α. This co-stimulation was more effective in some morphology changes and mediator release than FcεRI stimulation alone (Fifadara et al., 2010). Thus, CCR can contribute to the inflammatory and allergic responses by formation of cytokines, as a way to communicate between MC and other cells. Recently, the same group has identified 32 genes that were differentially regulated by a co-stimulation of antigen and the CCR1 ligand CCL3, compared to stimulation with antigen or CCL3 alone, in RBL-CCR1 transfected cells. Four genes were mostly up regulated 3 h post co-stimulation (Cd7, Rgs1, Emp1, RT1-S3), but only the CCL7 protein was expressed at a higher level 24 h following co-stimulation. Among chemokines and cytokines tested, only CCL2 protein showed higher expression levels and IL-6 was seen only after co-stimulation, although in a very low level (Aye et al., 2012). The authors suggested therefore that CCL2, CCL7, and IL-6 may be important for MC regulation in the late phase of the allergic response.

Another novel example of co-stimulation is the one between FcεRI and adenosine receptor. Nunomura et al. showed that co-stimulation of a low antigen dose together with adenosine can induce MC degranulation in a synergistic way, through cooperation of the two receptors mediated signaling. This was suggested to be relevant to the immediate asthma response upon bronchial
FIGURE 1 | Mast cells co-activation by IL-18, IL-33, TSLP, and TLR receptors.

challenge with low-dose allergen (Nunomura et al., 2010). It has also been shown that mBMMC mutant in the FcεRIβ-chain-ITAM could not be degranulated upon co-stimulation, through PI3K-signaling pathway (Nunomura et al., 2010). These findings can provide more detailed insight to which and how specific parts of the β chain and the PI3K-signaling are important for MC co-activation.

In mouse MC, thrombin, a serine protease, by binding to the protease-activated receptor (PAR)-1 TRAP(14) induces the secretion of IL-6 in a dose dependent fashion, but not of TNFα. Co-stimulation of low level thrombin with an allergen, can synergistically enhance IL-6 secretion through FcεRI signaling and the PI(3) and sphingosine-kinase pathways (Gordon et al., 2000).

Drube et al. reported a cross-activation of IL-33R and c-kit receptor in human and murine MC, after joining of IL-33R upon ligand binding, to a constitutively bound complex composed of c-kit and IL-1R accessory protein. In primary MC, the c-kit ligand SCF, is necessary for IL-33 induced cytokine production (Drube et al., 2010). Silver et al. showed that IL-33 in HMC-1 cells induced a synergistic activation effect together with adenosine, C5a, SCF, and NGF receptors. In primary hMC, IL-33R was also synergized with FcεRI activation (Silver et al., 2010).

CD48 was found to be a co-stimulatory receptor for inducing different effects in various hematopoietic cells by binding several ligands (Elishmereni and Levi-Schaffer, 2011). We have recently found that hCBMC and eosinophils can be directly activated by CD48 ligand/s (Elishmereni et al., 2011). In addition we detected some co-stimulatory effects when CBMC were activated by IgE-dependent mechanisms (Minai-Fleminger, Y., Levi-Schaffer, F., unpublished data).

CD84 is a self binding receptor from the signaling lymphocyte activating molecules (SLAM) family. However it was shown on transfected RBL-2H3 cells to inhibit FcεRI degranulation (Oliver-Vila et al., 2008). Additionally CD84 was found to be expressed on hMC (Alvarez-Errico et al., 2011), and shown to be tyrosine phosphorylated upon co-stimulation with FcεRI. This led to reduction in granule release and in the release of IL-8 and GM-CSF in LAD-2 cells and human CD34+ derived MC (Alvarez-Errico et al., 2011).

As reported in the past by our group, MC express DNAX accessory molecule 1 (DNAM-1, CD226) and eosinophils express its ligand Nectin-2 (CD112). It was shown that CD226 engagement with FcεRI induces an activating synergistic effect on MC and blocking of the ligand CD112 reduced the hyperactivity caused by IgE-dependent MC activation (Bachelet et al., 2006). To conclude, these few examples of co-stimulatory responses on MC can possibly help in understanding and foreseeing the complex allergic inflammatory response and be essential for the development of new anti-allergic therapy.

MC INHIBITORY RECEPTORS AND MC INHIBITION

Inhibitory receptors classically described on NK (Cantoni et al., 1999; for review, see Pegram et al., 2011) comprise two main families of the Ig receptor super-family and the c-type (calcium dependent) lectin superfamily. On MC, FcεRIIB, CD300, CD72, and sialic acid binding Ig-like lectins (Siglec)8, 7, etc., have been described (Karra and Levi-Schaffer, 2011). Since the FcεRIIB receptor has been extensively investigated (see Daeron et al., 2008; Bruhns et al., 2009) and we discussed some receptors bringing about MC inhibition, such as CB1, under their respective families, here we will consider only the most newly described typical IRs.

Inhibitory receptors expressed on MC can modulate their function by inhibiting typically the signaling from receptors associated with tyrosine kinases, i.e., FcεRI and c-kit (Figure 2). IRs contain immunoreceptor tyrosine based inhibition motifs (ITIMs) that down regulate the activation signals transmitted through immunoreceptor tyrosine based ligand ITAMs. The engagement of IRs suppresses cell activation by promoting dephosphorylation reactions. Upon activation of ITIM-containing receptors, tyrosine residues within the motifs become phosphorylated. This leads to the recruitment of protein phosphatases, Src homology 2 (SH) domain containing protein tyrosine phosphatase-1/2 (SHP-1 and SHP-2) and lipid phosphatases SH2 domain bearing
inositol phosphatase (SHIP1). SHP-1/2 inhibits the action of tyrosine kinase, while SHPI1 terminates the PI3K-mediated pathway (Karra and Levi-Schaffer, 2011). Herewith we are going to illustrate the CD300a, Siglec 7 and 8, and CD72 IRs.

The CD300 family of myeloid immunoglobulin receptors includes activating (CD300b, CD300e) and inhibitory (CD300a, CD300f) members, as well as molecules of uncertain functions presenting a negative charge within their TM domain (CD300c, CD300d; Martinez-Barriocanal et al., 2010). None of the activating receptors identified contains a charged glutamic acid residue in the TM that is present in CD300c, suggesting that CD300c might deliver activating signals via signaling proteins other than those previously observed or that CD300c is not an activating receptor (Lankry et al., 2010). The function of CD300d is related to the regulation of the expression of other CD300 molecules and the composition of CD300 complexes on the cell surface (Comas-Casellas et al., 2012).

The CD300 IR are type I TM glycoproteins with a single IgV-like extracellular domain and a membrane proximal region, a TM region, and a cytoplasmic region with ITIM motif (Lankry et al., 2010). The cytoplasmic domains of CD300a and CD300f contain internalization motifs and the cell surface expression of these molecules might be regulated, in part, by internalization (Clark et al., 2009). The expression of CD300a and CD300f was shown in MC (Clark et al., 2009), where CD300a presents on MC from nasal polyps, lungs, and on hCBMC (Bachelet et al., 2005) and its mouse ortholog LMIR-1, is expressed on mBMMC (Kumagai et al., 2003). CD300a is also expressed on NK, T cell subsets, neutrophils, eosinophils, monocytes DC, and more recently it has been characterized on basophils (Cantoni et al., 1999; Bachelet et al., 2005; Munitz et al., 2006a; Alvarez et al., 2008; Sabato et al., 2012).

It has been recently reported that CD300a interacts with polar lipids, including the major phospholipids of cell membranes, and is able to transduce intracellular signals after lipid binding. One of CD300a ligands is phosphatidylserine which directly binds CD300a and phosphorylates ITIM in the cytoplasmic portion of CD300a on BMMC (Nakahashi-Oda et al., 2012). Interestingly, Simhadri showed that CD300a phosphatidylethanolamine and phosphatidylserine bind to CD300a, and modulate the phagocytosis of dead cells. CD300a down regulates the uptake of apoptotic cells by macrophages and its ectopic expression in CD300a-negative cell lines also decreased the engulfment of dead cells (Simhadri et al., 2012). Using a co-transfection assay on THP-1 cells, Kim et al. (2012) showed that while CD300a blocked only MyD88 induced events, CD300f blocked both MyD88 and TRIF.

CD300a reduced survival of MC and eosinophils by decreasing the effect of c-kit on MC, and the IL-5, GM-CSF effect on eosinophils (Bachelet et al., 2005, 2008). Moreover a bi-specific Ab to CD300a and IgE inhibited acute airway inflammation in an experimental asthma mouse model and passive cutaneous anaphylaxis (Bachelet et al., 2008). Also a bi-specific Ab against CD300a and CCR3 inhibited chronic airway inflammation in murine asthma, possibly by its binding on both MC and eosinophils and their consequent inhibition (Munitz et al., 2006b). Disease-wise there is evidence for alterations in the expression and function of the CD300 family in patients with psoriasis (Clark et al., 2009).

Siglec-8 appears on hMCs at the same time as other MC markers such as FceRI (Karra et al., 2009). When cross-linked by mAbs on hpbMC, Siglec-8 does not lead to apoptosis as it does on eosinophils, but rather to strong inhibition of histamine and prostaglandin D2 secretion and of [Ca^{2+}] influx (Yokoi et al., 2008; Bochner, 2009; Karra et al., 2009). Siglec-8 is known to specifically recognize the sialoside sequence 6′-sulfo-sLex (Tateno et al., 2005). Siglec-8 has been shown to be associated with asthma (Gao et al., 2010). We have found Siglec 7, another lectin-binding IR, that was previously described on eosinophils (Munitz et al., 2006a) to be expressed and functional on hMC (Mizrahi,
S., Karra, L., Ben Zimra, M., and Levi-Schaffer, F., unpublished data).

CD72 (Lyb-2) is an ITIM-containing 45 kDa type II TM protein of the C-type lectin family (Wu and Bondada, 2009) whose natural ligands have been identified as CD100 or Semaphorin 4D (Sem4D). CD72, which is considered to be an important co-receptor regulating B-cell activation (Wu and Bondada, 2009), is also expressed on mouse NK cells (Alcon et al., 2009) and on hPBMC and human cell lines (Kataoka et al., 2010). Ligation of CD72 reduced SCF-mediated proliferation, chemotaxis, and MCP-1 (or CCL2) production in hMCs and the suppression of growth of HMC-1.2 harboring the gain-of-function mutation in KIT gene (Kataoka et al., 2010).

In conclusion IR, that have been shown to mostly modulate on MC the activation of FceRI and C-kit, may have by themselves or by cooperation with other receptors, inhibitory functions on other receptors not necessarily linked to tyrosine kinase mechanism, although this still has to be thoroughly investigated.

REFERENCES

Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., Klukner, S., Meyer, N., O'Mahony, L., Palomares, O., Rhyner, C., Ouaked, N., Schaftartzik, A., van de Veen, W., Zeller, S., Zimmermann, M., and Akdis, C. A. (2011). Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases. J. Allergy Clin. Immunol. 127, 701–721 e701–e770.

Akira, S., and Takeda, K. (2004). Toll-like receptor signaling. Nat. Rev. Immunol. 4, 499–511.

Alcon, V. L., Luther, C., Balce, D., and Takeda, F. (2009). B-cell co-receptor CD72 is expressed on NK cells and inhibits IFN-gamma production but not cytotoxicity. Eur. J. Immunol. 39, 826–832.

Allakhverdi, Z., Comeau, M. R., Jesup, H. K., Yoon, B. R., Brewer, A., Chartier, S., Paquette, N., Ziegler, S. F., Sarfati, M., and Delespesse, G. (2007). Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J. Exp. Med. 204, 253–258.

Altinova, A. E., Yetkin, I., Akbay, E., Bukan, N., and Arslan, M. (2008). Serum IL-18 levels in patients with type 1 diabetes: relations to metabolic control and microvascular complications. Cytotherapy 42, 217–221.

Alvarez, Y., Tang, X., Coligan, J. E., and Borrego, F. (2008). The CD300a (IRP60) inhibitory receptor is rapidly up-regulated on human neutrophils in response to inflammatory stimuli and modulates CD32a (FcgammaRIIa) mediated signaling. Mol. Immunol. 45, 253–258.

Alvarez-Errico, D., Oliver-Vila, I., Ainsua-Enrich, E., Gilfillan, A. M., Picado, C., Sayos, J., and Martin, M. (2011). CD86 negatively regulates IgE high-affinity receptor signaling in human mast cells. J. Immunol. 187, 5577–5586.

An, W. P., Palmer, G., and Gabay, C. (2008). IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 223, 20–38.

Asadi, S., Aylendratos, K. D., Angelidou, A., Miniati, A., Sismanopoulou, N., Vasiadi, M., Zhang, B., Kalogeromitros, D., and Theoharides, T. C. (2012). Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1. J. Immunol. 182, 324–329.

Askren, P. W., Herzog, W. R., Millet, L., Palawi, V., Ramabhadran, R., Rochester, C., Geha, G. P., and Ptak, W. (1991). Serotonin initiation of delayed-type hypersensitivity: mediation by a primitive Thy-1 antigen-specific clone or by specific monomeric IgE antibody. Skin Pharmacol. 4(1Suppl. 1), 25–42.

Aye, C. C., Toda, M., Morohoshi, K., and Ono, S. J. (2012). Identification of genes and proteins specifically regulated by costimulation of mast cell Fcepsilon receptor I and chemokine receptor 1. Exp. Mol. Pathol. 92, 267–274.

Bachelet, I., Munizit, A., Munktadat, U., and Levi-Schaffer, F. (2006). Mast cell costimulation by CD226/CD112 (DNAM-1/Nectin-2): a novel interface in the allergic process. J. Biol. Chem. 281, 27190–27196.

Bachelet, I., Munizit, A., Moretta, A., Moretta, L., and Levi-Schaffer, F. (2005). The inhibitory receptor IRP60 (CD300a) is expressed and functional on human mast cells. J. Immunol. 175, 7898–7995.

Baslund, B., Tvede, N., Danskeoid-Samsoe, B., Larsson, P., Panayi, G., Petersen, J., Petersen, L. J., Beurskens, F. J., Schuurman, J., van de Winkel, I. G., Parren, P. W., Graice, J. A., Jongsbloed, S., Liew, F. Y., and McInnes, I. B. (2005). Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 52, 2686–2692.

Berger, M., Gray, J. A., and Roth, B. L. (2009). The expanded biology of serotonin. Annu. Rev. Med. 60, 355–366.

Bochner, B. S. (2009). Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin. Exp. Allergy 39, 317–324.

Brightling, C. E., Kaur, D., Berger, M., Morgan, A. J., Wardlaw, A. J., and Bradding, P. (2005). Differential expression of CCR3 and CXCR3 by human lung and bone marrow-derived mast cells: implications for tissue mast cell migration. J. Leukoc. Biol. 77, 759–766.

Bruhn, P., Iannasci, B., England, P., Mancardi, D. A., Hernandez, N., Jorieux, S., and Daeron, M. (2009). Specificity and affinity of human Fgamer receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716–3725.

Buhring, H. J., Streble, A., and Valentin, P. (2004). The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int. Arch. Allergy Immunol. 133, 317–329.

Bulanova, E., Budagian, V., Orsina, Z., Koch-Nolte, H., Haag, F., and Bullone-Paus, S. (2009). ATP induces P2X7 receptor-independent cytokine and chemokine expression through P2X1 and P2X3 receptors in murine mast cells. J. Leukoc. Biol. 85, 692–702.

Bulanova, E., and Bullone-Paus, S. (2010). P2 receptor-mediated signaling in mast cell biology. Purinergic Signal. 6, 3–17.

Burnstock, G. (2007). Purine and pyrimidine receptors. Cell. Mol. Life Sci. 64, 1471–1483.

Cantoni, C., Bottino, C., Augugliaro, R., Morelli, L., Marcenaro, E., Castri, R., Vitale, M., Pende, D., Sivori, S., Millo, R., Biassoni, R., Moretta, L., and Moretta, A. (1999). Molecular and functional characterization of IRP60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur. J. Immunol. 29, 3148–3159.

Cevikbas, F., and Steinhoff, M. (2012). IL-33: a novel danger signal system in atopic dermatitis. J. Invest. Dermatol. 132, 1326–1329.

CONCLUSION

Mast cells express a variety of receptors that enable them, both in activating or inhibiting ways, to modulate immune response and can be used as treatment targets in disease conditions. While some of the described receptors such as H4 and purinergic receptors, we are close to developing a drug, with others, such as TSLP, more basic studies on their functions are needed. Overall, evidence shows that MC receptors have a strong therapeutic potential but still a better understanding of their pathophysiological roles, expression and their role in the immune system is required in order to develop effective and side effect free therapeutic interventions in the near future.

ACKNOWLEDGMENTS

This work was supported by COST (European Cooperation in Science and Technology) Action BM1007 (Mast Cells and Basophil – Targets for Innovative Therapies) of the European Community.
Elishmereni, M., and Levi-Schaffer, F. (2011). Physical attenuation of experimental pruritus. *J. Allergy Clin. Immunol.* 128, 531–537.

Elishmereni, M., and Levi-Schaffer, F. (2011). Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. *J. Allergy Clin. Immunol.* 119, 176–183.

Edwards, M. J. (2008). Therapy directed against thymic stromal lymphopoietin. *Drug News Perspect.* 21, 312–316.

Elishmereni, M., Alenius, H. T., Brading, T., Bradding, P., and Levi-Schaffer, F. (2011). Physical interactions between mast cells and eosinophils: a novel mechanism enhancing eosinophil survival in vitro. *Allergy* 66, 376–385.

Elishmereni, M., and Levi-Schaffer, F. (2011). CD44 is a co-stimulatory receptor of immunity. *Int. J. Biochem. Cell Biol.* 43, 25–28.

Fang, C., Siew, L. Q., Corrigan, C. J., and Ying, S. (2010). The role of thymic stromal lymphopoietin in allergic inflammation and chronic obstructive pulmonary disease. *Arch. Immunol. Ther. Exp. (Warsz.)* 58, 81–90.

Feng, C., Mery, A. G., Beller, E. M., Favorov, C., and Boyce, J. A. (2004). Adenine nucleotides inhibit cytokine generation by human mast cells through a Gs-coupled receptor. *Int. Immunol.* 16, 753–7547.

Fiaudara, N. H., Beer, F., Ono, S., and Ono, S. J. (2010). Interaction between activated chemokine receptor 1 and Fc epsilon RI at membrane rafts promotes communication and F-actin-rich cytoskeleton extensions between mast cells. *Int. Immunol.* 22, 113–128.

Forseyth, R., and Ennis, M. (1999). Adenosine, mast cells and asthma. *Inflamm. Res.* 48, 301–307.

Francisco, H. L., Demorrow, S., Franchitto, A., Venter, J. K., Mancini, R. A., White, M. A., Meng, F., Ueno, Y., Carpino, G., Renzi, A., Baker, K. K., Shine, H. E., Francis, T. C., Gaudio, E., Alpino, G. D., and Onori, S. J. (2010). Interaction between mast cells. *Allergy* 65, 69–83.

Gracie, J. A., Forsey, R. J., Chan, W. L., Gilmour, A., Leung, B. P., Greer, M. R., Kennedy, C. R., Carter, R., Wei, X., Xu, D., Field, M., Foulis, A., Liew, F. Y., and McInnes, I. B. (1999). A proinflammatory role for IL-18 in rheumatoid arthritis. *J. Clin. Invest.* 104, 1393–1401.

Gramatopoulos, D. K. (2011). Insights into mechanisms of corticostatin-releasing hormone receptor signal transduction. *Br. J. Pharmacol.* 166, 85–97.

Gri, G., Piconese, S., Frosi, B., Manfro, V., Merluzzi, S., Tripodo, C., Viola, A., Odom, S., Rivera, J., Colombo, M. P., and Pucillo, C. E. (2008). Polymorphisms in the sialic acid-binding immunoglobulin-like lectin-8 (Siglec-8) gene are associated with susceptibility to asthma. *BMC Immunol.* 9, 29.

Hara, M., Obara, K., Hirota, T., Yoshimoto, T., Hitomi, Y., Sakashita, M., Doi, S., Miyatake, A., Fujita, K., Enomoto, T., Taniguchi, M., Higaishi, N., Futuknotom, Y., Nakashita, K., Nakamura, Y., and Tami, S. (2009). A functional polymorphism in IL-18 is associated with severity of bronchial asthma. *Am. J. Respir. Crit. Care Med.* 180, 1048–1055.

Hauswirth, A. W., Escalona, L., Prados, A., Nunez, R., Mirik, I., Kneidinger, M., Florian, S., Sonneck, K., Vales, A., Scherthanher, G. H., Sanchez-Munoz, L., Sperr, W. R., Buhring, H. I., Orloa, A., and Valenti, P. (2008). CD203c is overexpressed on regulatory mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking. *Int. J. Immunopathol. Pharmacol.* 21, 797–806.

He, R., and Geha, R. S. (2010). Thymic stromal lymphopoietin. *Annu. N. Y. Acad. Sci.* 1183, 13–24.

Hebbar, H., and Grecins, R. K. (2002). IL-18 regulates intestinal mastocytosis and Th2 cytokine production independently of IFN-gamma during Trichinella spiralis infection. *J. Immunol.* 169, 2533–2560.

Hofstra, C., L., Desai, P. J., Thurmond, R. L., and Fung-Leung, W. P. (2003). Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. *J. Pharmacol. Exp. Ther.* 305, 1212–1211.

Homey, B., and Bunnemann, E. (2004). Chemokines and inflammatory skin diseases. *Eur. J. Pharmacol.* 65, 89–93.

Hone, B., Mellor, S., Savinko, T., Aalenius, H., and Lauerma, A. (2007). Modulation of chemokines by staphylococcal superantigen in atopic dermatitis. *Chem. Immunol.* 93, 181–194.

Homey, B., Steinhoff, M., Ruzicka, T., and Leung, D. Y. (2006). Cytokines and chemokines orchestrate atopic skin inflammation. *J. Allergy Clin. Immunol.* 118, 178–189.

Howlett, A. C. (2005). Cannabionid receptor signaling. *Handb. Exp. Pharmacol.* 168, 33–72.

Hua, C., L., Nelsen, C. V., and Bryce, P. J. (2010). IL-33 is produced by mast cells and regulates IgE-dependent inflammation. *PLoS ONE* 5, e11944. doi:10.1371/journal.pone.0011944

Hua, X., Chason, K. D., Patel, J. Y., Naselsky, W. C., and Tilley, S. L. (2011). IL-4 amplifies the pro-inflammatory effect of adenosine in human mast cells by changing expression levels of adenosine receptors. *PLoS ONE* 6, e24987. doi:10.1371/journal.pone.024987

Hueber, A. J., Alves-Filho, J. C., Aquith, D. L., Michels, C., Millar, N. L., Reilly, J. H., Graham, G. J., Liew, F. Y., Miller, A. M., and McInnes, I. B. (2011). IL-33 induces skin inflammation with mast cell and neutrophil activation. *Eur. J. Immunol.* 41, 2225–2237.

Hughes, P. J., Helgãte, S. T., and Church, M. K. (1984). Adenosine inhibits and potentiates IgE dependent histamine release from human lung mast cells by an A2 purinoceptor mediated mechanism. *Biochem. Pharmacol.* 33, 3847–3852.

Ilves, T., and Harvima, I. T. (2012). CD4+ T cells in atopic dermatitis lesions but not in normal skin express reduced levels of the mast cell activating protein CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-CD40L interaction. *Immunology* 12, 77–81.

Ilves, T., and Harvima, I. T. (2012). CD4+ T cells in atopic dermatitis lesions but not in normal skin express reduced levels of the mast cell activating protein CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-CD40L interaction. *Immunology* 120, 827–834.
Isaksen, D. E., Baumann, H., Zhou, B., Nivollet, S., Fars, A. G., Levin, S. D., and Zugerz, S. F. (2002). Uncoupling of proliferation and Stat5 activation in thymic stromal lymphopoiesis-mediated signal transduction. J. Immunol. 168, 3288–3294.

Ishimitsu, R., Nishimura, H., Yajima, J., Tatase, T., Kawauchi, H., and Yoshikai, Y. (2001). Overexpression of IL-15 in vivo enhances Tc1 response, which inhibits allergic inflammation in a murine model of asthma. J. Immunol. 166, 1991–2001.

Ito, T., Wang, Y. H., Duramad, O., Hori, T., Delepesse, G. J., Watanabe, N., Qin, F. X., Yao, C. Z., Cao, W., and Liu, Y. J. (2005). TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med. 202, 1213–1223.

IUPHAR Receptor Database. (2008). 5-Hydroxytryptamine receptors. International Union of Basic and Clinical Pharmacology. Available at: www.iuphar-db.org. [Accessed April 11, 2008].

Jackson, N. E., Wang, H. W., Tedla, N., McNeil, H. P., Gezcy, C. L., Collins, A., Grimm, M. C., Hampartzoumian, T., and Hunt, J. E. (2005). IL-15 induces mast cell migration via a permiss- toxin-sensitive receptor. Eur. J. Immunol. 35, 2376–2385.

Jolly, P. S., Bektas, M., Olivera, A., Gonzalez-Espinoza, C., Proia, R. L., Rivera, J., Malste, S., and Spiegel, S. (2004). Transactivation of sphingosine-1-phosphate receptors by FcgpsunR1 triggering is required for normal mast cell degranulation and chemotaxis. J. Exp. Med. 199, 1689–1697.

Jolly, P. S., Bektas, M., Watterson, K. R., Sankala, H., Payne, S. G., Malster, S., and Spiegel, S. (2005). Expression of Spk1p impairs degranulation and motility of RBL-2H3 mast cells by desensitizing S1P receptors. Blood 105, 4736–4742.

Jüremalm, M., and Nilsson, G. (2005). Chemokine receptor expression by mast cells. Chem. Immunol. Allergy 87, 130–144.

Jüremalm, M., Olsson, N., and Nilsson, G. (2002). Selective CCL5/RANTES-induced mast cell migration through interactions with chemokine receptors CCR1 and CCR4. Biochem. Biophys. Res. Commun. 297, 480–485.

Kaplán, B. L., Lawver, J. E., Karmaus, W. L., Harkema, J. R., and Weiner, H. L. (2002). IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4+ T cells via CD40-CD40 ligand interactions. J. Neuroimmunol. 125, 134–140.

Karra, L., Berent-Maor, B., Ben-Zimra, M., and Levi-Schaffer, F. (2009). Are we ready to downregulate mast cells? Curr. Opin. Immunol. 21, 708–714.

Karra, L., and Levi-Schaffer, F. (2011). Down-regulation of mast cell responses through ITIM containing inhibitory receptors. Adv. Exp. Med. Biol. 716, 143–159.

Kashivakura, J., Yokoi, H., Sato, H., and Okayama, Y. (2004). T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsil and lung-cultured mast cells. J. Immunol. 173, 5247–5257.

Kataoka, T., R., Kumanogoh, A., Bandara, G., Metcalfe, D. D., and Gilfillan, L. A. M. (2010). CD27 negatively regulates KIT-mediated responses in human mast cells. J. Immunol. 184, 2468–2475.

Kim, E. J., Lee, S. M., Suk, K., and Lee, W. H. (2012). CD300a and CD300f differentially regulate the MyD88 and TRIF-mediated TLR signalling pathways through activation of SHP-1 and/or SHP-2 in human monocytic cell lines. Immunology 135, 226–235.

King, B. F., and Burnstock, G. (2002). “Purinergic receptors,” in Understanding G Protein-Coupled Receptors and Their Role in the CNS, eds M. Pangalos and C. Davies (Oxford, Oxford University Press), 422–438.

Knisz, J., Banks, A., Mckeg, L., Metcalfe, D. D., Rothman, P. B., and Brown, J. M. (2009). Loss of SOCS7 in mice down-regulates mast cell response to FimH-expressing E. coli. J. Immunol. 185, 2877–2886.

Le, T. A., Takai, T., Vu, A. T., Kinoshita, H., Chen, X., Ikeda, S., Ogawa, H., and Okumura, K. (2011). Flagellin induces the expression of thymic stromal lymphopoietin in human keratinocytes via toll-like receptor 5. Int. Arch. Allergy Immunol. 155, 31–37.

Levi-Schaffer, F., and Eliasaf, R. (2009). Mast cell stabilizing properties of antihistamines. J. Invest. Dermatol. 129, 2549–2551.

Liew, F. Y., Pittman, N. I., and Mcintire, I. B. (2010). Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10, 103–110.

Lippert, U., Artuc, M., Gruitzkau, A., Babina, M., Guhl, S., Haase, I., Blaschke, V., Zachmann, M., Knosalla, M., Middel, P. Kruger-Krasagakis, S., and Henz, B. M. (2004). Human skin mast cells express H2 and H4, but not H3 and H5 receptors LMIR1 and 2 derived from membrane IgG. J. Immunol. 173, 125, 134–143.

Liu, Y. J. (2007). Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation. J. Allergy Clin. Immunol. 120, 238–244; quiz 245–246.

Lorenzen, L., Dingley, A. J., Jacques, Y., and Grotzing, J. (2006). The structure of the interleukin-15 alpha receptor and its implications for ligand binding. J. Biol. Chem. 281, 6642–6647.

Luther, S. A., Bidgel, A., Hargreaves, D. C., Schmidt, A., Xu, Y., Panayidi, I., Mateloubian, M., and Oyster, J. G. (2002). Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J. Immunol. 169, 424–433.

Malaviya, R., and Abraham, S. N. (2001). Mast cell modulation of immune responses to bacteria. Immunol. Rev. 179, 16–24.

Malaviya, R., Gao, Z., Thankavel, K., van der Merwe, P. A., and Abraham, S. N. (1999). The mast cell tumor necrosis factor alpha response to FimH-expressing Escherichia coli is mediated by the glycosylphosphatidylinositol anchored molecule CD48. Proc. Natl. Acad. Sci. U.S.A. 96, 8101–8115.

Markovic, D., Punn, A., Lehnert, H., and Grammatopoulos, D. K. (2008). Intracellular mechanisms regulating corticotropin-releasing hormone receptor-2beta endocytosis and interaction with extracellularly regulated kinase 1/2 and p38 mitogen-activated protein kinase signaling cascades. Mol. Endocrinol. 22, 699–706.

Martinez-Barricano, A., Comas-Casellas, E., Schwartz, S. J., Martin, M., and Sayos, J. (2010). CD300 heterocomplexes, a new and family-restricted mechanism for myeloid cell signaling regulation. J. Biol. Chem. 285, 41781–41794.

Masini, E., Blandina, P., Brunelleschi, S., and Mannionni, P. F. (1982). Evidence for H2-receptor-mediated inhibition of histamine release from isolated rat mast cells. Agents Actions 12, 85–88.

Matsuda, H., Prak, W., and Askenea, P. W. (1995). Role of mast cells versus basophils in IgE-dependent local ear skin release of the serotonin required to initiate contact sensitivity in mice. Int. Arch. Allergy Immunol. 107, 364.

McCurdy, J. D., Lin, T. J., and Marshall, J. S. (2001). Toll-like receptor 4-mediated activation of murine mast cells. J. Immunol. 167, 616–23.

McCurdy, J. D., Olynnych, T. J., Mahler, L. H., and Marshall, J. S. (2003). Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J. Immunol. 171, 4915–4918.

Frontiers in Immunology | Molecular Innate Immunity August 2012 | Volume 3 | Article 238 | 14
The immune/inflammatory response,” in *Adrenal Physiology and Diseases*, Chap. 9, ed. G. Chrousos. Available at: www.endotext.org/adrenal/adrenal9.html

Morse, K. L., Behan, J., Laz, T. M., West, R. E. Jr., Greenfeder, S. A., Anthes, J. C., Umland, S. W., Fan, Y., Hipkin, R. W., Gonsiorek, W., Shin, N., Gustafson, E. L., Qiao, X., Wang, S., Hedrick, J. A., Greene, J., Bayne, M., and Monsma, F. J. Ir. (2001). Cloning and characterization of a novel human histamine receptor. *J. Pharmacol. Exp. Ther.* 296, 1058–1066.

Moret, E., Woo, T., Advincula, R., Gaozol, S., and Ma, A. (2008). IL-15Rα/alpha chaperones IL-15 to stable dendirict cell membrane complexes that activate NK cells via transpresentation. *J. Exp. Med.* 205, 1213–1225.

Munitz, A., Bachelet, I., Eliasar, R., Moretta, A., Moretta, L., and Levi-Schaffer, F. (2006a). The inhibitory receptor IRP60 (CD300A) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. *Blood* 107, 1996–2003.

Munitz, A., Bachelet, I., and Levi-Schaffer, F. (2006b). Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300A. *J. Allergy Clin. Immunol.* 118, 1082–1089.

Munitz, A., Bachelet, I., and Levi-Schaffer, F. (2007). CD48 as a novel target in asthma therapy. *Recent Pat. Inflamm. Allergy Drug Discov.* 1, 9–12.

Munoz, S., Hernandez-Pando, R., Abrah- am, S. N., and Enciso, J. A. (2003). Mast cell activation by Mycobacterium tuberculosis: mediating in asthma by a bispecific antibody fragment linking CCR3 to CD300A. *J. Allergy Clin. Immunol.* 118, 5590–5596.

Nakahashi-Oda, C., Tahara-Hanaoka, S., Honda, S., Shibuya, K., and Shibui, A. (2012). Identification of phosphatidylserine as a ligand for the CD300A immunoreceptor. *Biochem. Biophys. Res. Commun.* 417, 646–650.

Nakanishi, K., Yoshimoto, T., Tsut- sumi, M., and Harima, H. (2001). Interleukin-18 regulates both Th1 and Th2 responses. *Annu. Rev. Immunol.* 19, 423–474.

Nezi, M., Trianti-Dimoleni, V., and Mas- torakos, G. (2010). “Corticotropin-releasing hormone (CRH) and the immune/inflammatory response,” in *Adrenal Physiology and Diseases*, Chap. 9, ed. G. Chrousos. Available at: www.endotext.org/adrenal/adrenal9.html

Novick, D., Kim, S. H., Fantuzzi, G., Reznikov, L. L., Dinnarello, C. A., and Rubinstein, M. (1999). Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. *Immunity* 10, 127–136.

Novumura, S., Gon, Y., Yoshimaru, T., Kashiwakura, J., Kawakami, T., and Ra, C. (2010). Fc epsilonRIbeta-chain ITAM amplifies PTKS-signaling to ensure synergistic degranulation response via Fc epsilonRI and adenosine receptors. *Eur. J. Immunol.* 40, 1205–1217.

Ohkubo, T., Shibata, M., Inose, M., Kaya, H., and Takahashi, H. (1994). Autoregulation of histamine release via the histamine H3 receptor on mast cells in the rat skin. *Arch. Int. Pharmacodyn. Ther.* 328, 307–314.

Okita, Y., Yamada, Y., and Katsuoka, K. (2001). Expression of IL-18 in psoriasis. *Arch. Dermatol. Res.* 293, 334–342.

Okayama, Y., Okumura, S., Sagara, H., Yuki, K., Sasaki, T., Watanabe, N., Furi, M., Sugiyama, K., Takeda, K., Fukida, T., Saito, H., and Ra, C. (2009). FcepsilonRIbeta-chain ITAM amplifies PTKS-signaling to ensure synergistic degranulation response via Fc epsilonRI and adenosine receptors. *Eur. J. Immunol.* 40, 1205–1217.

Pegram, H. J., Andrews, D. M., Smyth, M. J., Darcy, P. K., and Kershaw, M. H. (2011). Activating and inhibitory receptors of natural killer cells. *Immunol. Cell Biol.* 89, 216–224.

Pertwee, R. G. (2006). The pharmacol- ogy of cannabinoid receptors and their ligands: an overview. *Int. J. Obes. (Lond.)* 30(Suppl. 1), S13–S18.

Pietrzk, A., Wierzbicki, M., Wiktorska, M., and Brezinska-Blaszczek, E. (2011). Surface TLIR2 and TLIR4 expression on mature rat mast cells can be affected by some bacterial components and proinflammatory cytokines. *Mediators Inflamm.* 2011, 427–473.

Pilot, C., Heron, A., Cochois, V., Tardivel-Lacombe, J., Lignseau, X., Schwartz, J. C., and Arrang, J. M. (2002). A detailed mapping of the histamine H3 receptor and its gene transcripts in rat brain. *Neuroscience* 114, 173–193.

Pini, A., Mannioni, G., Pellegrini- Giampietro, D., Passani, M. B., Mas- troiannini, R., Bani, D., and Masini, E. (2012). The role of cannabinoids in inflammation modulation of aller- gic respiratory disorders, inflamma- tory pain and ischemic stroke. *Curr. Drug Targets* 13, 984–993.

Plater-Zyberk, C., Coosten, L. A., Helsen, M. M., Sattanet-Roche, P., Siegfried, C., Alouani, S., van de Loo, F. A., Graber, P., Aloni, S., Cirillo, R., Lubberts, E., Dinarello, C. A., van den Berg, W. B., and Chvatychlo, V. (2001). Therapeutic effect of neu- tralizing endogenous IL-18 activ- ity in the collagen-induced model of arthritis. *J. Clin. Invest.* 108, 1825–1832.

Price, M. M., Kapitonov, D., Allegood, J., Milsiten, S., Oskeritzian, C. A., and Spiegel, S. (2009). Sphinngosine-1-phosphate induces development of functionally mature chymase-expressing human mast cells from hematopoietic progenitors. *FASEB J.* 23, 3506–3515.

Prof, T., and Baker, E. N. (2009). Pili in Gram-negative and Gram-positive bacteria – structure, assembly and their role in disease. *Cell. Mol. Life Sci.* 66, 613–635.

Ritter, M., El-Nour, H., Hiedblad, M. A., Butterfield, J. H., Beck, O., Stephanson, N., Holst, M., Giscombe, R., Armitia, E. C., and Nordlind, K. (2012). Serotonin and its 5-HT1 receptor in human mastocytosis. *Immunopharmacol. Immunotoxicol.* 34, 267–285.

Rocha-de-Souza, C. M., Berent-Maoz, B., Mankuta, D., Moses, A. E., and Levi-Schaffer, F. (2008). Human mast cell activation by Staphylococ- cus aureus: interleukin-8 and tumor necrosis factor alpha release and...
the role of Toll-like receptor 2 and CD48 molecules. *Infect. Immun.* 76, 4489–4497.

Roehmert, Y., and Leonard, W. J. (2008). Thymic stromal lymphopoeitin: a new cytokine in asthma. *Curr. Opin. Pharmacol.* 8, 249–254.

Rozentieck, J. I., Letournau, R., Sugiharto, M., Spansos, C., Gorbach, J., and Theoharides, T. C. (1999). Differential effect of histamine 3 receptor-active agents on brain, but not peritoneal, mast cell activation. *J. Pharmacol. Exp. Ther.* 290, 1427–1435.

Sabato, V., Verweij, M. M., Brodu, C. H., Levi-Schaffer, F., Gibbs, B. E., de Clerck, L. S., Schiavino, D., and Ego, D. B. (2012). CD300a is expressed on human basophils and seem to inhibit IgE/FcepsilonRI-dependent anaphylactic degranulation. *Cytometry B Clin. Cytom.* 82, 132–138.

Sanchez, T., Skoura, A., Wu, M. T., Caserly, B., Harrington, E. O., and Hla, T. (2007). Induction of vascular permeability by the sphinogosine-1-phosphate receptor 2-CD147 and its downstream effectors ROCK and PTEN. *Arterioscler. Thromb. Vasc. Biol.* 27, 1312–1318.

Shikotra, A., Choy, D. F., Ohri, C. A., Sanchez, T., Skoura, A., Wu, M. T., and Gillilan, A. M. (2010). TLR-mediated signaling pathways circumvent the requirement for DAP12 in mast cells for the induction of inflammatory mediator release. *Eur. J. Immunol.* 40, 3557–3569.

Spiegel, S., and Milstien, S. (2011). The outs and the ins of sphingosine-1-phosphate in immunity. *Nat. Rev. Immunol.* 11, 403–415.

Steiner, M. A., and Wojta, C. T. (2008). Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. *Prog. Brain Res.* 170, 397–432.

Sugawara, K., Biro, T., Tsuruta, D., Toth, B. I., Kromminga, A., Zakany, N., Zimmer, A., Funk, W. G., Bimmer, Z., and Paus, R. (2012). Endocannabinoids limit excessive mast cell maturation and activation in human skin. *J. Allergy Clin. Immunol.* 129, 726–739.

Supajatura, V., Ushio, H., Nakao, A., Akira, S., Okumura, K., Ra, C., and Ogawa, H. (2002). Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. *J. Clin. Invest.* 109, 1351–1359.

Tajima, S., Oshikawa, K., Tominaga, S., and Sugiyama, Y. (2003). The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. *Chest* 124, 1206–1214.

Takai, T. (2012). TSLP expression: cellular sources, triggers, and regulatory mechanisms. *Allergol. Int.* 61, 3–17.

Takeshita, K., Sakai, K., Bacon, K. B., and Gantner, F. (2003). Critical role of histamine H4 receptor in leukotriene B4 production and mast cell-dependent neutrophil recruitment induced by zymosan in vivo. *J. Pharmacol. Exp. Ther.* 307, 1072–1078.

Tateno, H., Crocker, P. R., and Paulson, J. C. (2005). Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfotyrosine Lewis X as a preferred glycan ligand. *Glycobiology* 15, 1125–1135.

Taylor, B. C., Zaph, C., Troy, A. E., Du, Y., Guild, K. J., Comeau, M. R., and Artsis, D. (2009). TSLP regulates intestinal immunity and inflammation in mouse models of helminth infection and colitis. *J. Exp. Med.* 206, 655–667.

Theoharides, T. C., Singh, L. K., Boucher, W., Pang, X., Letournau, R., Webster, E., and Chrousos, G. (1998). Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. *Endocrinology* 139, 403–413.

Thomassen, E., Bird, T. A., Renshaw, B. R., Kennedy, M. K., and Sims, J. E. (1998). Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1Rrp1 leads to activation of signaling pathways similar to those used by interleukin-1. *J. Interferon Cytokine Res.* 18, 1077–1088.

Tilly, B. C., Tertoollen, L. G., Remorie, R., Ladoux, A., Verlaan, L., de Laat, S. W., and Moolenaar, W. H. (1990). Histamine as a growth factor and chemoaattractant for human carcinoma and melanoma cells: action through Ca(2+)-mobilizing H1 receptors. *J. Cell Biol.* 110, 1211–1215.

Van Kolen, K., and Slegers, H. (2006). Integration of P2Y receptor-activated signal transduction pathways in G protein-dependent signaling networks. *Purinergic Signal.* 2, 451–469.

Vieira, R. P., Muller, T., Grimm, M., Von Gellerich, V., Vetter, B., Burk, T., Cacko, S., Ayata, C. K., Sorichter, S., Rebaye, B., Zeiser, R., Ferrari, D., Kirschbaum, A., Gissel, G., Girchow, J. C., Boenema, J. M., and Ildzo, M. (2011). Purinergic receptor type 6 contributes to airway inflammation and remodeling in experimental allergic airway inflammation. *Am. J. Respir. Crit. Care Med.* 184, 215–223.

Villadés, L. S., Schurman, J., Beurskens, F., Dam, R. N., Maenhout, G., Van Den Driessche, J. K., van Boevingen, J. M., and Van der Valk, P. (2008). IL-33 exacerbates antigen-induced airway inflammation through activation of Th2 cell. *Eur. J. Immunol.* 38, 2709–2719.

Wang, L., Gantz, I., and Delvalle, J. (1996). Histamine H2 receptor activators adenylate cyclase and PLC through separate G-protein-dependent pathways. *Am. J. Physiol.* 271, G613–G620.

Wang, Y. H., and Li, Y. J. (2007). OX40-OX40L interactions: a promising therapeutic target for allergic diseases? *J. Clin. Invest.* 117, 3655–3657.

Wang, Z., Lai, Y., Bernard, J. I., Macleod, D. T., Cogen, A. L., Moss, B., and Di Nardo, A. (2012). Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor SIP2P and releasing anti-inflammatory peptides. *J. Immunol.* 188, 345–357.

Wiener, Z., Poczta, P., Racz, M., Nagy, G., Tolgyesi, G., Molnar, V., Jaeger, J., Buzas, E., Gerbe, E., Papp, Z., Rigo, J., and Falus, A. (2008). IL-18 induces a marked gene expression profile change and increased Ccl5 (1-309) production in mouse mucosal mast cell homologs. *Int. Immunol.* 20, 1565–1573.

Willott, I., Mirikian, L., Westwick, J., and Ward, S. G. (2010). Evidence for PL3K-dependent CXCR3 agonist-induced degranulation of human cord blood-derived mast cells. *J. Immunol.* 147, 2367–2377.

Wooley, D. E., and Te llow, L. C. (2000). Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. *Arthritis Res.* 2, 65–74.

Wu, H. J., and Bondada, S. (2009). CD72, a coreceptor with both positive and negative effects on B lymphocyte development and function. *J. Clin. Immunol.* 29, 12–21.

Xu, D., Jiang, H. R., Kevin, P., Li, Y., Mu, R., Fraser, A. R., Pitman, N., Kurowska-Stolarska, M., Mckenzie, A. N., McInnes, I. B., and Liew, F. Y. (2008). IL-33 exaggerates antigen-induced arthritis by activating mast cells. *Proc. Natl. Acad. Sci. U.S.A.* 105, 10913–10918.

Ying, S., Yang, X., and Rato ti, J., Meng, Q., Fang, C., Cousins, D., Zhang, G., Gu, S., Gao, Z., Shami, B., Edwards, M. J., Lee, T. H., and Corrigan, C. J. (2008). Expression and cellular provenance of thymic stromal lymphopoeitin and chemo kines in patients with severe asthma and chronic obstructive pulmonary disease. *J. Immunol.* 181, 2790–2798.

Ying, S., O’Connor, B., Ratto ti, J., Meng, Q., Fang, C., Cousins, D., Wang, L., Gantz, I., and Delvalle, J. (1996). Histamine H2 receptor activators adenylate cyclase and PLC through separate G-protein-dependent pathways. *Am. J. Physiol.* 271, G613–G620.

Frontiers in Immunology | Molecular Innate Immunity

August 2012 | Volume 3 | Article 238 | 16

Migalovich-Sheikhet et al. Receptors on mast cells
chemokines and disease severity. J. Immunol. 174, 8183–8190.
Yip, K. H., Wong, L. L., and Lau, H. Y. (2009). Adenosine: roles of different receptor subtypes in mediating histamine release from human and rodent mast cells. Inflamm. Res. 58(Suppl. 1), 17–19.
Yokoi, H., Choi, O. H., Hubbard, W., Lee, H. S., Canning, B. J., Lee, H. H., Rya, S. D., Von Gunten, S., Bickel, C. A., Hudson, S. A., Macglashan, D. W. Jr., and Bochner, B. S. (2008). Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. J. Allergy Clin. Immunol. 121, 499–505 e491.
Yoo, J., Omori, M., Gyarmati, D., Zhou, B., Aye, T., Brewer, A., Comeau, M. R., Campbell, D. J., and Ziegler, S. F. (2005). Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J. Exp. Med. 202, 541–549.
Young, M. R., and Matthews, J. P. (1995). Serotonin regulation of T-cell subpopulations and of macrophage accessory function. Immunology 84, 148–152.
Yu, S., Stahl, E., Li, Q., and Ouyang, A. (2008). Antigen inhalation induces mast cells and eosinophils infiltration in the guinea pig esophageal epithelium involving histamine-mediated pathway. Life Sci. 82, 324–330.
Zhang, F., Huang, G., Hu, B., Song, Y., and Shi, Y. (2011). A soluble thymic stromal lymphopoietin (TSLP) antagonist, TSLPR-immunoglobulin, reduces the severity of allergic disease by regulating pulmonary dendritic cells. Clin. Exp. Immunol. 164, 256–264.
Zhu, Y., Michalovich, D., Wu, H., Tan, K. B., Dryko, G. M., Mannan, I. I., Boyce, R., Alston, J., Tierney, L. A., Li, X., Herrity, N. C., Vawter, L., Sarau, H. M., Ames, R. S., Davenport, C. M., Hieble, J. P., Wilson, S., Bergsma, D. J., and Fitzgerald, L. R. (2001). Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol. Pharmacol. 59, 434–441.
Ziegler, S. F., and Artis, D. (2010). Sensing the outside world: TSLP regulates barrier immunity. Nat. Immunol. 11, 289–293.
Zimmermann, N., King, N. E., Laporte, I., Yang, M., Mishra, A., Pope, S. M., Muntel, E. E., Witte, D. P., Pegg, A. A., Foster, P. S., Hamid, Q., and Rothenberg, M. E. (2003). Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J. Clin. Invest. 111, 1863–1874.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 23 April 2012; accepted: 16 July 2012; published online: 02 August 2012.
Citation: Migalovich-Sheikhet H, Friedman S, Mankuta D and Levi-Schaffer F (2012) Novel identified receptors on mast cells. Front. Immun. 3:238. doi: 10.3389/fimmu.2012.00238
This article was submitted to Frontiers in Molecular Innate Immunity, a specialty of Frontiers in Immunology.
Copyright © 2012 Migalovich-Sheikhet, Friedman, Mankuta and Levi-Schaffer. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.